MedPath

扬子江药业集团有限公司

Ownership
-
Established
2001-03-27
Employees
-
Market Cap
-
Website
http://www.yangzijiang.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

210

NMPA:210

Drug Approvals

Pomalidomide Capsules

Product Name
泊马度胺胶囊
Approval Number
国药准字H20253721
Approval Date
Mar 25, 2025
NMPA

Pomalidomide Capsules

Product Name
泊马度胺胶囊
Approval Number
国药准字H20253720
Approval Date
Mar 25, 2025
NMPA

Iguratimod Tablets

Product Name
艾拉莫德片
Approval Number
国药准字H20253637
Approval Date
Mar 18, 2025
NMPA

Omega-3-acid ethyl ester 90 Soft Capsules

Product Name
ω-3脂肪酸乙酯90软胶囊
Approval Number
国药准字H20249504
Approval Date
Dec 1, 2024
NMPA

Diquafosol Sodium Eye Drops

Product Name
地夸磷索钠滴眼液
Approval Number
国药准字H20247253
Approval Date
Oct 29, 2024
NMPA

Etomidate Medium and Long Chain Fat Emulsion Injection

Product Name
依托咪酯中/长链脂肪乳注射液
Approval Number
国药准字H20249023
Approval Date
Oct 9, 2024
NMPA

Esketamine Hydrochloride Injection

Product Name
盐酸艾司氯胺酮注射液
Approval Number
国药准字H20244027
Approval Date
Jun 18, 2024
NMPA

Tafluprost Eye Drops

Product Name
他氟前列素滴眼液
Approval Number
国药准字H20243690
Approval Date
May 15, 2024
NMPA

Tegafur, Gimeracil and Oteracil Potassium Capsules

Product Name
替吉奥胶囊
Approval Number
国药准字H20243202
Approval Date
Feb 23, 2024
NMPA

Tegafur, Gimeracil and Oteracil Potassium Capsules

Product Name
替吉奥胶囊
Approval Number
国药准字H20243203
Approval Date
Feb 23, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 21
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.